VivoSim Labs (FRA:4OR) Beneish M-Score: 34.67 (As of Jun. 25, 2026)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.13
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Beneish M-Score?

VivoSim Labs FRA:4OR 39 Beneish M-Score is 34.67 as of Jun. 25, 2026. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.13. The stock has 4 warning signs investors should review. Among 831 Biotechnology companies, VivoSim Labs ranks worse than 97.35% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 34.67 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for VivoSim Labs's Beneish M-Score or its related term are showing as below:

FRA:4OR' s Beneish M-Score Range Over the Past 10 Years
Min: -5.79   Med: -3.49   Max: 34.67
Current: 34.67

During the past 13 years, the highest Beneish M-Score of VivoSim Labs was 34.67. The lowest was -5.79. And the median was -3.49.


VivoSim Labs Beneish M-Score Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Beneish M-Score Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -5.30 -3.62 0.00

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.79 0.00 1.78 2.31 34.67

FRA:4OR vs AZTR, GRI, BIXT: Beneish M-Score Comparison

For the Biotechnology subindustry, VivoSim Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Beneish M-Score falls into.


FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of VivoSim Labs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 32.2547+0.528 * 0.9558+0.404 * 0.2818+0.892 * 1.1062+0.115 * 0.6586
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8872+4.679 * 1.458614-0.327 * 0.3998
=33.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €0.89 Mil.
Revenue was 0.022 + 0.024 + 0.032 + 0.047 = €0.13 Mil.
Gross Profit was 0.022 + 0.024 + 0.032 + 0.047 = €0.13 Mil.
Total Current Assets was €5.16 Mil.
Total Assets was €5.94 Mil.
Property, Plant and Equipment(Net PPE) was €0.66 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.20 Mil.
Selling, General, & Admin. Expense(SGA) was €6.73 Mil.
Total Current Liabilities was €2.11 Mil.
Long-Term Debt & Capital Lease Obligation was €0.04 Mil.
Net Income was -2.298 + -2.168 + -2.465 + 6.338 = €-0.59 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0.00 Mil.
Cash Flow from Operations was -1.939 + -2.026 + -3.416 + -1.882 = €-9.26 Mil.
Total Receivables was €0.03 Mil.
Revenue was 0.023 + 0.027 + 0.036 + 0.027 = €0.11 Mil.
Gross Profit was 0.021 + 0.026 + 0.034 + 0.027 = €0.11 Mil.
Total Current Assets was €2.01 Mil.
Total Assets was €3.67 Mil.
Property, Plant and Equipment(Net PPE) was €1.39 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.26 Mil.
Selling, General, & Admin. Expense(SGA) was €6.85 Mil.
Total Current Liabilities was €2.81 Mil.
Long-Term Debt & Capital Lease Obligation was €0.52 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.892 / 0.125) / (0.025 / 0.113)
=7.136 / 0.221239
=32.2547

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.108 / 0.113) / (0.125 / 0.125)
=0.955752 / 1
=0.9558

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5.159 + 0.66) / 5.944) / (1 - (2.006 + 1.391) / 3.671)
=0.02103 / 0.074639
=0.2818

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.125 / 0.113
=1.1062

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.255 / (0.255 + 1.391)) / (0.203 / (0.203 + 0.66))
=0.154921 / 0.235226
=0.6586

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6.727 / 0.125) / (6.854 / 0.113)
=53.816 / 60.654867
=0.8872

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.038 + 2.114) / 5.944) / ((0.519 + 2.805) / 3.671)
=0.362046 / 0.905475
=0.3998

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.593 - 0 - -9.263) / 5.944
=1.458614

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

VivoSim Labs has a M-score of 33.06 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 34.67 mean?
VivoSim Labs (FRA:4OR) has a Beneish M-Score of 34.67 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #809 out of 831 companies in the Biotechnology industry, placing it in the top 97.4%.
Is VivoSim Labs' Beneish M-Score too high?
VivoSim Labs' current Beneish M-Score is 34.67. Based on the distribution chart, VivoSim Labs ranks #809 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Beneish M-Score compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #809 out of 831 companies for Beneish M-Score. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Beneish M-Score is 34.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Beneish M-Score of 34.67. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current Beneish M-Score is 34.67. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Beneish M-Score is 34.67 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.

Key valuation signals for FRA:4OR:

  • Beneish M-Score: 34.67
  • GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.13
GF Value